Search results for: 'cro ad pfas clinical'

21 Sep 2022  |  North America  |  Market Research

Drinking Water PFAS Treatment—United States: Forecast to 2026

Future Growth Potential of Sample Testing to Help Map the Presence of PFAS

Infographics

×

Growing concerns regarding the presence of perfluoroalkyl and polyfluoroalkyl substances (PFAS) in surface water, groundwater, wastewater, soil, and air are making state and national level regulations in the United States regarding permissible contaminant limits more stringent. There are growing efforts among municipal utilities and different indus...

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

PFAS are highly persistent in the environment and are associated with a wide range of serious health risks, resulting in increasing demand for effective management solutions. This study offers a comprehensive analysis of the drinking water PFAS management industry in the United States, highlighting important growth drivers and restraints. The ne...

As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allo...

This report examines how decentralized clinical trials (DCTs), enabled by blockchain, digital twins, and artificial intelligence, are reshaping global clinical research. It traces the shift from site-centric to patient-centric models and quantifies the growing scale, globalization, and complexity of clinical trials that make decentralization necess...

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide....

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

Per- and polyfluoroalkyl substances (PFAS) present substantial environmental and health risks. Their complex structure makes them resistant to natural breakdown and allows them to accumulate in living organisms, posing a potential health risk. Growing evidence of PFAS contamination in surface water, groundwater, wastewater, soil, and air is compell...

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will ...